



# Ticagrelor Improves Endothelial Function by Decreasing Circulating Epidermal Growth Factor (EGF)

Francesco Vieceli Dalla Sega<sup>1,2,3</sup>, Francesca Fortini<sup>1,2,3</sup>, Giorgio Aquila<sup>1,2</sup>, Rita Pavasini<sup>4</sup>, Simone Biscaglia<sup>4</sup>, Davide Bernucci<sup>4</sup>, Annamaria Del Franco<sup>4</sup>, Elisabetta Tonet<sup>4</sup>, Paola Rizzo<sup>3,5</sup>, Roberto Ferrari<sup>2,3,4</sup> and Gianluca Campo<sup>3,4\*</sup>

<sup>1</sup> Department of Medical Sciences, University of Ferrara, Ferrara, Italy, <sup>2</sup> Maria Cecilia Hospital, GVM Care & Research, E.S. Health Science Foundation, Cotignola, Italy, <sup>3</sup> Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy, <sup>4</sup> Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, Italy, <sup>5</sup> Laboratory for Technologies of Advanced Therapies, University of Ferrara, Ferrara, Italy

## OPEN ACCESS

### Edited by:

Pasquale Pagliaro,  
Università degli Studi di Torino, Italy

### Reviewed by:

Marco Moscarelli,  
Imperial College London,  
United Kingdom  
Rossella Rota,  
Bambino Gesù Ospedale Pediatrico  
(IRCCS), Italy

### \*Correspondence:

Gianluca Campo  
cmpgic@unife.it

### Specialty section:

This article was submitted to  
Clinical and Translational Physiology,  
a section of the journal  
Frontiers in Physiology

Received: 08 February 2018

Accepted: 19 March 2018

Published: 05 April 2018

### Citation:

Vieceli Dalla Sega F, Fortini F, Aquila G,  
Pavasini R, Biscaglia S, Bernucci D,  
Del Franco A, Tonet E, Rizzo P,  
Ferrari R and Campo G (2018)  
Ticagrelor Improves Endothelial  
Function by Decreasing Circulating  
Epidermal Growth Factor (EGF).  
*Front. Physiol.* 9:337.  
doi: 10.3389/fphys.2018.00337

Ticagrelor is one of the most powerful P2Y<sub>12</sub> inhibitor. We have recently reported that, in patients with concomitant Stable Coronary Artery Disease (SCAD) and Chronic Obstructive Pulmonary Disease (COPD) undergoing percutaneous coronary intervention (PCI), treatment with ticagrelor, as compared to clopidogrel, is associated with an improvement of the endothelial function (Clinical Trial NCT02519608). In the present study, we showed that, in the same population, after 1 month treatment with ticagrelor, but not with clopidogrel, there is a decrease of the circulating levels of epidermal growth factor (EGF) and that these changes in circulating levels of EGF correlate with on-treatment platelet reactivity. Furthermore, in human umbilical vein endothelial cells (HUVEC) incubated with sera of the patients treated with ticagrelor, but not with clopidogrel there is an increase of p-eNOS levels. Finally, analyzing the changes in EGF and p-eNOS levels after treatment, we observed an inverse correlation between p-eNOS and EGF changes only in the ticagrelor group. Causality between EGF and eNOS activation was assessed *in vitro* in HUVEC where we showed that EGF decreases eNOS activity in a dose dependent manner. Taken together our data indicate that ticagrelor improves endothelial function by lowering circulating EGF that results in the activation of eNOS in the vascular endothelium.

**Keywords:** epidermal growth factor (EGF), eNOS, ticagrelor, endothelial function, stable coronary artery disease (SCAD), chronic obstructive pulmonary disease (COPD), EGF

## INTRODUCTION

Ticagrelor is one of the most powerful P2Y<sub>12</sub> inhibitor (Motovska et al., 2018). Unlike other P2Y<sub>12</sub> inhibitors, ticagrelor exerts some pleiotropic effects acting mainly on endothelial function in several settings (Schnorbus et al., 2014; Li et al., 2016; Campo et al., 2017; Kim et al., 2017). In a recent randomized clinical trial, in patients with concomitant stable coronary artery disease (SCAD) and chronic obstructive pulmonary disease (COPD) undergoing percutaneous coronary intervention (PCI), we demonstrated that 1 month treatment with ticagrelor, as compared to clopidogrel, is associated with an improvement in markers of endothelial function, such as a reduction of endothelial apoptosis and endothelial nitric oxide (NO) production, a reduction in ROS levels in PBMC as well as a more effective reduction of platelet reactivity (Campo et al., 2017).

At the state of the art the reason of the effect of ticagrelor on endothelial function is not completely characterized. One of the possible mechanism behind its pleiotropic effects could be related to the ability of ticagrelor to increase adenosine plasma concentration by inhibiting the adenosine type-1 equilibrative nucleoside transporter (ENT1) (Sumaya and Storey, 2017). Nonetheless, this view has been argued by some studies showing that ticagrelor is not always able to increase adenosine plasma concentration (van den Berg et al., 2015). This implies that increased plasma adenosine, at least in some circumstances, may not represent the only mechanism by which ticagrelor improves endothelial function and that other molecular targets may be involved.

It is well-established that circulating cytokines, such as TNF- $\alpha$ , cause increased endothelial apoptosis and inhibit eNOS activity in endothelial cells (Agnoletti et al., 1999; Valgimigli et al., 2003). Hence, this is a sub-analysis of The comparison between ticAgrelor and clopidogrel effect on endoThelial platelet ANd iNflammation parameters in patiEnts with SCAD and COPD study, aiming to investigate the underlying mechanism of ticagrelor-mediated improvement of endothelial function, comparing the effect on cytokines level of 1 month treatment of ticagrelor vs. clopidogrel, and then assessing p-eNOS levels in endothelial cells treated with patient's sera and investigating possible correlations between cytokines changes and this marker of endothelial function.

## MATERIALS AND METHODS

### Study Design/Population/Randomization and Interventions

This is a sub-study of the clinical trial “The comparison between ticAgrelor and clopidogrel effect on endoThelial platelet ANd iNflammation parameters in patiEnts with SCAD and COPD” undergoing PCI (NATHAN-NEVER). The clinical trial was registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier NCT02519608. The protocol was approved by “Comitato Etico Unico della Provincia di Ferrara.” All subjects gave written informed consent in accordance with the Declaration of Helsinki. Details of the design of the study and the outcomes of the clinical trial are reported in Campo et al. (2017). Briefly, population inclusion criteria were: (1) age >18 years; (2) ability to provide informed written consent; (3) SCAD diagnosis with coronary artery angiography (CAA) and PCI; (4) COPD diagnosis confirmed by spirometry. Main exclusion criteria were: (1) prior administration of P2Y<sub>12</sub> inhibitor (clopidogrel, ticlopidine, prasugrel, ticagrelor) or of anticoagulant drugs; (2) known intolerance to clopidogrel or ticagrelor; (3) prior intracranial hemorrhage; (4) cerebrovascular accident and/or active major bleeding and/or major surgery within the last 30 days and (5) other known inflammatory chronic disorders. Randomization /interventions: 46 patients were enrolled and randomly assigned to receive, on top of aspirin, clopidogrel, or ticagrelor. To minimize potential confounding effects, randomization was stratified according to the presence of diabetes and COPD severity.

### Inflammation Parameters (Cytokines/Chemokines) Analysis

Sera ( $n = 20$  per group) were kept at  $-80^{\circ}\text{C}$  and thawed only once before performing the MILLIPLEX MAP Human Cytokine/Chemokine Panel assay (Merck Millipore, Billerica, MA), a multiplex immunoassay, which allows the simultaneous detection and quantification of the following 29 human cytokines/chemokines: epidermal growth factor (EGF), Eotaxin, granulocyte colony-stimulating factor (G-CSF), granulocyte monocyte colony-stimulating factor (GM-CSF), interferon (IFN)  $-\alpha_2$ , IFN- $\gamma$ , interleukin (IL)-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17 $\alpha$ , IL-1 receptor antagonist (ra), IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, inducible protein (IP)-10 (CXCL10), monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1 $\alpha$ , MIP-1 $\beta$ , tumor necrosis factor (TNF)  $-\alpha$ , TNF- $\beta$ , and vascular endothelial growth factor (VEGF). Samples were processed following the manufacturer's instructions and data were analyzed by MAGPIX instrument provided with the MILLIPLEX-Analyst Software.

### Platelet Function Analysis

On-treatment platelet reactivity (PR) was assessed by the VerifyNow<sup>TM</sup> system (Accumetrics, San Diego, CA, USA), using a specific assay to evaluate P2Y<sub>12</sub> inhibitors (VerifyNow P2Y<sub>12</sub><sup>TM</sup>). The results were expressed as P2Y<sub>12</sub> reaction unit (PRU).

### Cell Culture

HUVECs pools, purchased from Life Technologies, were plated on 1.5% gelatin-coated tissue culture dishes and maintained in basal medium M200 (Life Technologies, Carlsbad, CA, USA) containing 2% FBS and growth factors (EGM-2, Life Technologies, Carlsbad, CA, USA) at  $37^{\circ}\text{C}$  with 5% CO<sub>2</sub>. Cells from passages 2 to 4 were actively proliferating (70–90% confluent) when samples were harvested and analyzed. EGM-2 contains EGF among other growth factors, in the experiments where HUVECs were treated with different concentrations of EGF cells were seeded and grown in EGM-2 without EGF and different concentrations of recombinant human EGF (rhEGF) were added 48 h prior to cell lysis.

### ELISA

Activation of eNOS in HUVEC was assessed by ELISA (Cell Signaling Technology, Danvers, USA) with antibody specific for the phosphorylated form of eNOS (p-eNOS Ser1177) following manufacturer instructions. Briefly, HUVECs were treated for 48 h with patient's sera ( $n = 18$  per group) or were grown in M200 supplemented with EGM2 without EGF. Analysis of eNOS activation were performed after 48 h incubation with patient's sera or different concentrations of rhEGF. Protein concentration of each lysate was quantified by using Pierce BCA Protein Assay Kit (Thermo Scientific, Wilmington, USA) and 10  $\mu\text{g}$  of total protein extract was used for each well. Data were expressed as p-eNOS levels as absorbance at 488 nm.

## Western Blot

Western blot analysis was carried out to detect expression of total eNOS and  $\beta$ -actin as previously described (Fortini et al., 2017). Briefly, cells were lysed in RIPA buffer and protein concentration of each lysate was quantified by Pierce BCA Protein Assay Kit (Thermo Scientific, Wilmington, USA). The same amount of total protein (10  $\mu$ g) was loaded in each lane, then proteins were separated on 7% NuPAGE gels (Life Technologies, Carlsbad, CA, USA). Proteins were transferred to PVDF membranes and were incubated overnight at 4°C with primary antibodies, washed three times in TBS/Tween 0.1%, and then incubated for 1 h at room temperature with secondary peroxidase-conjugated antibodies. Membranes were washed three times in TBS/Tween 0.1% and developed using Western Lightning ECL Pro (PerkinElmer, Waltham, MA). Images were obtained by exposing membranes to Chemidoc. Immunoreactive bands were analyzed with ImageLab analysis software (Bio Rad, Hercules, CA). Mouse antibody against eNOS was from BD Biosciences (Franklin Lakes, New Jersey, USA), mouse monoclonal against  $\beta$ -actin and secondary anti-mouse antibody were from Sigma-Aldrich (St. Louis, MS, USA).  $\beta$ -actin was used for normalization in the quantitative evaluation of western blots after verifying that  $\beta$ -actin levels were not affected by any treatment in comparison to total protein evaluated by staining with Ponceau (Sigma-Aldrich, Saint Louis, MO).

## Statistical Analysis

Normal distribution of the variables was explored with the Kolmogorov–Smirnov test and with the Shapiro test ( $\alpha = 0.05$ ). Variables were presented with mean  $\pm$  standard deviation or median  $\pm$  interquartile range. Normally distributed variables were compared by *t*-test and one-way ANOVA; otherwise the Mann-Whitney U and Kruskal-Wallis tests were used. For comparisons between two groups two-tailed unpaired Student's *t*-tests were used except for the comparisons in the before and after analysis in which two-tailed paired Student's *t*-tests were used. When more than two groups were compared, one-way ANOVA with Student-Newman-Keuls method for multiple comparisons was used. Correlations between EGF and p-eNOS or, EGF and PR were assessed using Spearman correlation test ( $\alpha = 0.05$ ). In cells experiments with exogenous EGF results are expressed as mean  $\pm$  SD of at least three independent experiments. Statistical analysis was performed with Graphpad Prism 6.0 (Graphpad Software, La Jolla, CA).

## RESULTS

### Cytokines/Chemokines

As previously reported, after 1 month treatment of ticagrelor or clopidogrel, serum levels of inflammation-related cytokines/chemokines, in patients with concomitant SCAD and COPD undergoing PCI, did not statistically differ (Campo et al., 2017). In this study, the effect of each treatment on cytokine level was further investigated with a before and after statistical analysis. We found that there is a significant decrease in the serum levels of EGF in patients treated with ticagrelor, but not in the clopidogrel group. EGF serum concentration

was log- normally distributed, as tested with the Kolmogorov–Smirnov test. Accordingly, EGF levels in the different groups were expressed as log[EGF] (Figures 1A,B) and further analyses were performed using log-transformed EGF values. Difference between log[EGF] means before and after treatment with ticagrelor was 0.21 ( $p < 0.01$ ; 95% CI difference of means = 0.09–0.33).

### Correlation Between EGF Changes and Platelet Reactivity

As previously reported, ticagrelor is more powerful in inhibiting PR compared with clopidogrel (Lemesle et al., 2015; Campo et al., 2017). After 1-month treatment, changes in EGF levels correlated with on-treatment platelet reactivity ( $R = 0.355$ ;  $p = 0.020$ ) (Figure 2).

### Changes in p-eNOS Levels Changes and Correlation With EGF

In HUVECs treated with patient's sera we found an increase of p-eNOS only in those of patients treated with ticagrelor at 1 month compared to the baseline (OD 2.0 at baseline vs. 2.7 after 1 month;  $p < 0.01$ ). Furthermore, we observed a significant difference in p-eNOS levels between HUVEC treated with the sera of the two treatment groups (OD 2.1 vs. 2.7, clopidogrel, and ticagrelor, respectively;  $p < 0.01$ ) (Figure 3).



We then analyzed the changes in EGF and p-eNOS levels after 1 month treatment with the two different antiplatelet drugs. The efficacy in modulating EGF or p-eNOS of clopidogrel or ticagrelor was expressed as ratio of EGF or p-eNOS levels after 1 month over the respective EGF or p-eNOS at baseline. Fold-times changes of EGF ( $EGF_{1\text{month}}/EGF_{\text{baseline}}$ ) and of p-eNOS ( $p\text{-eNOS}_{1\text{month}}/p\text{-eNOS}_{\text{baseline}}$ ) are shown in Figures 4A,B. Ticagrelor was shown to be more powerful in decreasing EGF compared to clopidogrel ( $p = 0.042$ ) and also more efficient in increasing p-eNOS ( $p = 0.020$ ). In addition, correlation analyses between changes in EGF and in p-eNOS levels (Figures 5A,B) showed a correlation between EGF and p-eNOS ratio in the ticagrelor ( $R = -0.571$ ;  $p = 0.002$ ) but not in the clopidogrel group ( $R = 0.100$ ;  $p = 0.714$ ).

### Effect of Exogenous EGF on eNOS in HUVECs

To assess a possible causal relationship between EGF levels and eNOS activation we treated HUVEC with different concentrations of EGF and we evaluated p-eNOS levels. We found that p-eNOS levels quantified by ELISA were decreased by EGF in a dose-dependent manner (Figure 6A). In addition, we analyzed by western blotting the total eNOS content in HUVEC treated with different concentration of EGF and we found that also total eNOS protein was diminished by EGF in a dose-dependent manner (Figure 6B).

## DISCUSSION

In this study we report that, in patients with SCAD and COPD undergoing PCI, 1 month treatment with ticagrelor, but not with



clopidogrel, results in a decrease of serum EGF concentration (Figures 1A,B). EGF can be secreted in the blood stream by different cellular sources such as submandibular gland (Tsutsumi

et al., 1986), kidney (Staruschenko et al., 2013), and platelets (Ben-Ezra et al., 1990; Feng et al., 2012). However, the individual contribution of the different sources of circulating EGF as well as how the EGF levels are physiologically determined are not known.



EGF is a small protein constituted by 53 amino acids and three intramolecular disulfide bridges, and it is the founding member of the EGF-family of proteins. EGF acts by specifically binding to epidermal growth factor receptor (EGFR) on the cell membrane (Carpenter and Cohen, 1990). EGFR is a transmembrane receptor that controls signal transduction pathways that ultimately lead to survival, differentiation, and/or cell proliferation (Zeng and Harris, 2014). Activation of EGFR is known to be involved in many pathological processes such as endothelial dysfunction (Mehta et al., 2008), hypertension (Zhou et al., 2009), restenosis (Chan et al., 2003; Shafi et al., 2009), atherogenesis (Dreux et al., 2006), and cardiac remodeling (Iwamoto et al., 2003). More recently, it has been also shown that EGFR inhibition in T cells reduces atherosclerosis development (Zeboudj et al., 2018). The precise contribution of specific EGFR ligands is still poorly understood in the cardiovascular context but different lines of evidence have revealed that EGF can negatively affect endothelial function (Belmadani et al., 2008; Kassan et al., 2015), vascular tone regulation (Lundstam et al., 2007; Sumaya and Storey, 2017) and that it provokes proliferation of vascular smooth muscle cells (Berk et al., 1985).



We found a correlation, even if not particularly strong ( $R = 0.350$ ), between changes in serum EGF concentrations and on-treatment platelet reactivity after pharmacological treatment

(Figure 2). Certainly, other factors could be involved in the level of PR and this will be the object of our future studies. EGF is present in platelets  $\alpha$ -granules from where it can be

secreted in the blood stream following degranulation (Lev-Ran et al., 1990; Blair and Flaumenhaft, 2009; Bertrand-Duchesne et al., 2010; Durante et al., 2013). Notably, it is known that inhibiting P2Y<sub>12</sub> receptors not only blocks platelet aggregation but also reduces release of mediators from  $\alpha$ -granules (Zhao et al., 2001; Storey et al., 2002). In this study, we did not investigate the mechanism by which EGF is decreased by ticagrelor, but based on the current knowledge, it appears likely that the observed decrease in the serum EGF could be due to a decrease in the EGF released by platelets.

Moreover, we showed that in HUVEC treated with sera of patients of the ticagrelor group at 1 month there is a higher activation of eNOS, in comparison to clopidogrel at the same time point (Figure 3). Interestingly, we found a negative correlation between changes in levels of circulating EGF and in eNOS activation in the ticagrelor arm (Figure 5B), but not in the clopidogrel group (Figure 5A). Taken together our data suggest that EGF interferes with eNOS activation. The role of EGF in decreasing eNOS activity has already been reported in animal models: in diabetic mice EGFR activation, resulting in eNOS activity impairment, is implicated in mesenteric resistance artery (MRA) dysfunction (Belmadani et al., 2008); in the same model, endogenous EGF decreased p-eNOS levels (Kassan et al., 2015). Here we showed *in vitro* that EGF is able to decrease both eNOS phosphorylation (Figure 6A) and total eNOS protein (Figures 6B,C) in a dose-dependent manner in HUVECs. Taken together our data indicate that ticagrelor is able to reduce circulating EGF levels and that, in turn, lower serum EGF positively affects the endothelial function by facilitating eNOS activity.





In conclusion, we showed that the positive effect of ticagrelor on endothelial function is, at least in part, mediated by its capacity to lower EGF that in turn results in a better eNOS activation. Our data suggest that lower platelet reactivity could result in lower EGF release by platelets through a P2Y<sub>12</sub>-mediated mechanism. This would imply that ticagrelor improvement of endothelial function is not only due to mechanisms linked to increased adenosine availability but could also be directly connected to its higher efficacy in diminishing platelet reactivity.

## AUTHOR CONTRIBUTIONS

FVDS and FF: Performed *in vitro* experiments; FVDS and PR: Analyzed the data and wrote the paper; GC and RF: Designed and supervised the clinical trial and provided critical revision of data;

## REFERENCES

Agnoletti, L., Curello, S., Bachetti, T., Malacarne, F., Gaia, G., Comini, L., et al. (1999). Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor. *Circulation* 100, 1983–1991.

Belmadani, S., Palen, D. I., Gonzalez-Villalobos, R. A., Boulares, H. A., and Matrougui, K. (2008). Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. *Diabetes* 57, 1629–1637. doi: 10.2337/db07-0739

Ben-Ezra, J., Sheibani, K., Hwang, D. L., and Lev-Ran, A. (1990). Megakaryocyte synthesis is the source of epidermal growth factor in human platelets. *Am. J. Pathol.* 137, 755–759.

Berk, B. C., Brock, T. A., Webb, R. C., Taubman, M. B., Atkinson, W. J., Gimbrone, M. A., et al. (1985). Epidermal growth factor, a vascular smooth muscle mitogen, induces rat aortic contraction. *J. Clin. Invest.* 75, 1083–1086. doi: 10.1172/JCI111772

Bertrand-Duchesne, M. P., Grenier, D., and Gagnon, G. (2010). Epidermal growth factor released from platelet-rich plasma promotes endothelial cell proliferation *in vitro*. *J. Periodont. Res.* 45, 87–93. doi: 10.1111/j.1600-0765.2009.01205.x

Blair, P., and Flaumenhaft, R. (2009). Platelet  $\alpha$ -granules: basic biology and clinical correlates. *Blood Rev.* 23, 177–189. doi: 10.1016/j.blre.2009.04.001

Campo, G., Vieceli Dalla Sega, F., Pavasini, R., Aquila, G., Gallo, F., Fortini, F., et al. (2017). Biological effects of ticagrelor over clopidogrel in patients with stable coronary artery disease and chronic obstructive pulmonary disease. *Thromb. Haemost.* 117, 1208–1216. doi: 10.1160/TH16-12-0973

Carpenter, G., and Cohen, S. (1990). Epidermal growth factor. *J. Biol. Chem.* 265, 7709–7712.

Chan, A. K., Kalmes, A., Hawkins, S., Daum, G., and Clowes, A. W. (2003). Blockade of the epidermal growth factor receptor decreases intimal hyperplasia in balloon-injured rat carotid artery. *J. Vasc. Surg.* 37, 644–649. doi: 10.1067/mva.2003.92

Dreux, A. C., Lamb, D. J., Modjtahedi, H., and Ferns, G. A. (2006). The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. *Atherosclerosis* 186, 38–53. doi: 10.1016/j.atherosclerosis.2005.06.038

Durante, C., Agostini, F., Abbruzzese, L., Toffola, R. T., Zanolin, S., Suine, C., et al. (2013). Growth factor release from platelet concentrates: analytic quantification and characterization for clinical applications. *Vox Sang.* 105, 129–136. doi: 10.1111/vox.12039

Feng, X., Scheinberg, P., Samsel, L., Rios, O., Chen, J., McCoy, J. P., et al. (2012). Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura. *J. Thromb. Haemost.* 10, 1616–1623. doi: 10.1111/j.1538-7836.2012.04757.x

Fortini, F., Vieceli Dalla Sega, F., Caliceti, C., Aquila, G., Pannella, M., Pannuti, A., et al. (2017). Estrogen receptor  $\beta$ -dependent Notch1 activation

GA, RP, SB, DB, and ADF: Participated to clinical assessments, collection of samples, and laboratory analyses. All authors reviewed data and results, and approved the final version of the manuscript.

## FUNDING

This study was partially supported by a research grant [ESR-14-10659] by AstraZeneca, which had no role in collecting, analyzing, and interpreting data; manuscript writing; and the decision to submit the paper for publication.

## ACKNOWLEDGMENTS

We thank Antonio Pannuti for his valuable advice in the statistical data analysis and interpretation.

protects vascular endothelium against tumor necrosis factor  $\alpha$  (TNF $\alpha$ )-induced apoptosis. *J. Biol. Chem.* 292, 18178–18191. doi: 10.1074/jbc.M117.790121

Iwamoto, R., Yamazaki, S., Asakura, M., Takashima, S., Hasuwa, H., Miyado, K., et al. (2003). Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. *Proc. Natl. Acad. Sci. U.S.A.* 100, 3221–3226. doi: 10.1073/pnas.0537588100

Kassan, M., Ait-Aissa, K., Ali, M., Trebak, M., and Matrougui, K. (2015). Augmented EGF receptor tyrosine kinase activity impairs vascular function by NADPH oxidase-dependent mechanism in type 2 diabetic mouse. *Biochim. Biophys. Acta Mol. Cell Res.* 1853, 2404–2410. doi: 10.1016/j.bbamcr.2015.05.032

Kim, H. K., Jeong, M. H., Lim, K. S., Kim, J. H., Lim, H. C., Kim, M. C., et al. (2017). Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. *Int. J. Cardiol.* 240, 326–331. doi: 10.1016/j.ijcard.2017.04.108

Lemesle, G., Schurtz, G., Bateurs, C., and Hamon, M. (2015). High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. *J. Thromb. Haemost.* 13, 931–942. doi: 10.1111/jth.12907

Lev-Ran, A., Hwang, D. L., and Snyder, D. S. (1990). Human serum and plasma have different sources of epidermal growth factor. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 259, R545–R548. doi: 10.1152/ajpregu.1990.259.3.R545

Li, Z., Li, Y., Zhang, T., Miao, W., and Su, G. (2016). Comparison of the influence of ticagrelor and clopidogrel on inflammatory biomarkers and vascular endothelial function for patients with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention: study protocol for a randomized controlled trial. *Trials* 17:75. doi: 10.1186/s13063-016-1168-9

Lundstam, U., Hägg, U., Bergmann Sverrisdottir, Y., Svensson, L. E., and Gan, L.-M. (2007). Epidermal growth factor levels are related to diastolic blood pressure and carotid artery stiffness. *Scand. Cardiovasc. J.* 41, 308–312. doi: 10.1080/14017430701439508

Mehta, V. B., Zhou, Y., Radulescu, A., and Besner, G. E. (2008). HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis. *Growth Factors* 26, 301–315. doi: 10.1080/08977190802393596

Motovska, Z., Hlinomaz, O., Kala, P., Hromadka, M., Knot, J., Varvarovsky, I., et al. (2018). 1-year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. *J. Am. Coll. Cardiol.* 71, 371–381. doi: 10.1016/j.jacc.2017.11.008

Schnorbus, B., Daiber, A., Jurk, K., Warnke, S., König, J., Krahn, U., et al. (2014). Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, controlled study. *BMJ Open* 4:e005268. doi: 10.1136/bmjopen-2014-005268

Shafi, S., Lamb, D., Modjtahedi, H., and Ferns, G. (2009). Periadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation

- after angioplasty in a hypercholesterolaemic rabbit. *Int. J. Exp. Pathol.* 91, 224–234. doi: 10.1111/j.1365-2613.2009.00700.x
- Staruschenko, A., Palygin, O., Ilatovskaya, D. V., and Pavlov, T. S. (2013). Epidermal growth factors in the kidney and relationship to hypertension. *Am. J. Physiol. Renal Physiol.* 305, F12–F20. doi: 10.1152/ajprenal.00112.2013
- Storey, R. F., Judge, H. M., Wilcox, R. G., and Heptinstall, S. (2002). Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y<sub>12</sub> receptor antagonist AR-C69931MX but not aspirin. *Thromb. Haemost.* 88, 488–494. doi: 10.1055/s-0037-1613242
- Sumaya, W., and Storey, R. F. (2017). Ticagrelor. *Int. Cardiol. Clin.* 6, 49–55. doi: 10.1016/j.iccl.2016.08.004
- Tsutsumi, O., Kurachi, H., and Oka, T. (1986). A physiological role of epidermal growth factor in male reproductive function. *Science* 233, 975–977. doi: 10.1126/science.3090686
- Valgimigli, M., Merli, E., Malagutti, P., Soukhomovskaia, O., Cicchitelli, G., Macri, G., et al. (2003). Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. *Arch. Biochem. Biophys.* 420, 255–261. doi: 10.1016/j.abb.2003.07.006
- van den Berg, T. N., El Messaoudi, S., Rongen, G. A., van den Broek, P. H., Bilos, A., Donders, A. R., et al. (2015). Ticagrelor does not inhibit adenosine transport at relevant concentrations: a Randomized Cross-Over Study in healthy subjects *in vivo*. *PLoS ONE* 10:e0137560. doi: 10.1371/journal.pone.0137560
- Zeboudj, L., Maitre, M., Guyonnet, L., Laurans, L., Joffre, J., Lemarie, J., et al. (2018). Selective EGF-receptor inhibition in CD4(+) T cells induces anergy and limits atherosclerosis. *J. Am. Coll. Cardiol.* 71, 160–172. doi: 10.1016/j.jacc.2017.10.084
- Zeng, F., and Harris, R. C. (2014). Epidermal growth factor, from gene organization to bedside. *Semin. Cell Dev. Biol.* 28, 2–11. doi: 10.1016/j.semcdb.2014.01.011
- Zhao, L., Bath, P., and Heptinstall, S. (2001). Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood *in vitro*. *Br. J. Pharmacol.* 134, 353–358. doi: 10.1038/sj.bjp.0704248
- Zhou, Y., Brigstock, D., and Besner, G. E. (2009). Heparin-binding EGF-like growth factor is a potent dilator of terminal mesenteric arterioles. *Microvasc. Res.* 78, 78–85. doi: 10.1016/j.mvr.2009.04.006

**Conflict of Interest Statement:** GC has received honoraria for lectures from Astrazeneca, Menarini, Abbott Vascular, Boston Scientific. RF has received honoraria for lectures from Servier.

The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Vieceli Dalla Sega, Fortini, Aquila, Pavasini, Biscaglia, Bernucci, Del Franco, Tonet, Rizzo, Ferrari and Campo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.